358 related articles for article (PubMed ID: 17887807)
1. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
Wolowacz SE; Roskell N; Kelly S; Maciver FM; Brand CS
Pharmacoeconomics; 2007; 25(10):863-79. PubMed ID: 17887807
[TBL] [Abstract][Full Text] [Related]
2. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
Colquitt JL; Jones J; Tan SC; Takeda A; Clegg AJ; Price A
Health Technol Assess; 2008 May; 12(16):iii-iv, ix-201. PubMed ID: 18462575
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
Earnshaw SR; Moride Y; Rochon S
Clin Ther; 2007 Sep; 29(9):2096-106; discussion 2094-5. PubMed ID: 18035208
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Hernández-Pastor LJ; Ortega A; García-Layana A; Giráldez J
Graefes Arch Clin Exp Ophthalmol; 2010 Apr; 248(4):467-76. PubMed ID: 19669678
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness model for neovascular age-related macular degeneration: comparing early and late treatment with pegaptanib sodium based on visual acuity.
Javitt JC; Zlateva GP; Earnshaw SR; Pleil AM; Graham CN; Brogan AJ; Shah SN; Adamis AP
Value Health; 2008; 11(4):563-74. PubMed ID: 18179676
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
Athanasakis K; Fragoulakis V; Tsiantou V; Masaoutis P; Maniadakis N; Kyriopoulos J
Clin Ther; 2012 Feb; 34(2):446-56. PubMed ID: 22289279
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.
Smith DH; Fenn P; Drummond M
Br J Ophthalmol; 2004 Sep; 88(9):1107-12. PubMed ID: 15317697
[TBL] [Abstract][Full Text] [Related]
9. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
[TBL] [Abstract][Full Text] [Related]
10. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
Brown GC; Brown MM; Brown HC; Kindermann S; Sharma S
Ophthalmology; 2007 Jun; 114(6):1170-8. PubMed ID: 17320964
[TBL] [Abstract][Full Text] [Related]
11. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].
Yanagi Y; Aihara Y; Fukuda T; Hashimoto H
Nippon Ganka Gakkai Zasshi; 2011 Sep; 115(9):825-31. PubMed ID: 22073599
[TBL] [Abstract][Full Text] [Related]
12. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
Gower EW; Cassard SD; Bass EB; Schein OD; Bressler NM
Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Sharma S; Brown GC; Brown MM; Hollands H; Shah GK
Ophthalmology; 2001 Nov; 108(11):2051-9. PubMed ID: 11713079
[TBL] [Abstract][Full Text] [Related]
14. Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations.
Grieve R; Guerriero C; Walker J; Tomlin K; Langham J; Harding S; Chakravathy U; Carpenter J; Reeves BC;
Ophthalmology; 2009 Dec; 116(12):2471-77.e1-2. PubMed ID: 19948278
[TBL] [Abstract][Full Text] [Related]
15. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
Takeda AL; Colquitt J; Clegg AJ; Jones J
Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
[TBL] [Abstract][Full Text] [Related]
16. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
[TBL] [Abstract][Full Text] [Related]
17. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
Quiram PA; Hassan TS; Williams GA
Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008
[TBL] [Abstract][Full Text] [Related]
18. Modelling cost effectiveness in neovascular age-related macular degeneration: the impact of using contrast sensitivity vs. visual acuity.
Butt T; Patel PJ; Tufail A; Rubin GS
Appl Health Econ Health Policy; 2014 Jun; 12(3):289-97. PubMed ID: 24610632
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
20. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden.
Panchmatia HR; Clements KM; Hulbert E; Eriksson M; Wittrup-Jensen K; Nilsson J; Weinstein MC
Acta Ophthalmol; 2016 Aug; 94(5):441-8. PubMed ID: 27061020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
